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Myristoylated alanine-rich C kinase substrate (MARCKS)
and MARCKS-related protein (MRP; MacMARCKS) are
protein kinase C substrates in diverse cell types. Activation
of murine macrophages by cytokines increases MRP ex-
pression, but infection with Leishmania promastigotes dur-
ing activation results in MRP depletion. We therefore ex-
amined the effect of Leishmania major LV39 on
recombinant MRP. Both live promastigotes and a soluble
fraction of LV39 lysates degraded MRP to yield lower mo-
lecular weight fragments. Degradation was independent of
MRP myristoylation and was inhibited by protein kinase
C-dependent phosphorylation of MRP. MRP was similarly
degraded by purified leishmanolysin (gp63), a Leishmania
surface metalloprotease. Degradation was evident at low
enzyme/substrate ratios, over a broad pH range, and was
inhibited by 1,10-phenanthroline and by a hydroxamate
dipeptide inhibitor of leishmanolysin. Using mass spectro-
metric analysis, cleavage was shown to occur within the
effector domain of MRP between Ser92 and Phe93, in ac-
cordance with the substrate specificity of leishmanolysin.
Moreover, an MRP construct in which the effector domain
had been deleted was resistant to cleavage. Thus, Leishma-
nia infection may result in leishmanolysin-dependent hy-
drolysis of MRP, a major protein kinase C substrate in
macrophages.
Myristoylated alanine-rich C kinase substrate (MARCKS)1
and MARCKS-related protein (MRP), also known as Mac-
MARCKS, are members of a highly acidic myristoylated family
of protein kinase C (PKC) substrates (1, 2). The primary struc-
tures of MARCKS and MRP exhibit significant homology, in-
cluding a highly basic stretch of amino acid residues known as
the effector domain (also as the phosphorylation site domain),
which contains the serine residues subject to PKC-dependent
phosphorylation as well as binding sites for calmodulin and
actin. Whereas MARCKS is widely distributed in diverse cell
types, MRP is present primarily in brain and reproductive
tissue (3, 4) as well as in macrophages, where it was first
characterized (5). The biologic functions of MARCKS proteins
are unknown. Due to their high effector domain homology, it is
also possible that MRP and MARCKS play overlapping roles in
some cells. In macrophages, both proteins colocalize in the
cytosol in association with components of the actin cytoskeleton
(6–9) and consequently are thought to participate in major
cellular responses such as phagocytosis, motility, and mem-
brane trafficking.
The expression of MARCKS proteins appears to be highly
regulated, and in vitro studies have demonstrated up- or down-
regulation of MARCKS at both the transcriptional and post-
transcriptional levels (5, 10, 11). One mechanism of post-tran-
scriptional regulation involves proteolytic degradation. Spizz
and Blackshear (12) recently identified cathepsin B as a cellu-
lar MARCKS-cleaving enzyme in fibroblasts. They suggested
that cleavage might occur within lysosomes as a result of spe-
cific lysosomal targeting sequences identified within the
MARCKS primary sequence. At least one cathepsin B-depend-
ent cleavage site was identified within the effector domain,
whereas a second site was three amino acids amino-terminal to
the effector domain. These results were consistent with the
inhibition of MARCKS cleavage observed upon PKC-dependent
phosphorylation of its effector domain serines (13).
We recently suggested that MRP levels might also be regu-
lated by proteolysis under certain conditions (14). Activation of
murine macrophages by bacterial lipopolysaccharide or cyto-
kines strongly up-regulates MRP mRNA and protein expres-
sion (5, 14). However, infection of macrophages with promas-
tigotes of the obligate intracellular parasite Leishmania at the
time of activation or up to 48 h post-activation results in sig-
nificant MRP depletion (14). Moreover, experiments with
[3H]myristate-labeled macrophages (14) and Western blot
analysis of macrophage lysates using an antibody directed
against the C terminus of MRP2 revealed the appearance of
lower molecular weight MRP fragments in Leishmania-in-
fected cells. These studies suggested that a parasite enzyme
might be capable of degrading MRP.
Leishmania promastigotes reside in the midgut of the phle-
botomine sand fly and invade host macrophages during a sand
fly bite. Promastigotes express a number of proteolytic en-
zymes that may play various roles in host invasion, evasion of
the anti-parasite immune response, or degradation of host pro-
teins (reviewed in Ref. 15). One such enzyme, the zinc metal-
loprotease leishmanolysin, also known as promastigote surface
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protease or gp63, is expressed at very high density (up to 5 3
105 molecules/cell) at the parasite surface (16), but its physio-
logic role is still unclear. Leishmanolysin is a glycosylphos-
phatidylinositol-anchored glycoprotein with neutral metallo-
proteinase activity for various denatured protein substrates
(16), but attempts to identify a physiologically relevant sub-
strate have been unsuccessful. However, a study of synthetic
peptide substrates allowed the determination of a consensus
cleavage sequence with a hydrophobic residue at the P19 site
and basic amino acid residues at the P29 and P39 sites (17). We
show here that recombinant MRP is a substrate for leishmano-
lysin and that a predominant cleavage site (Ser922Phe93-
Lys94-Lys95) corresponds to the above-mentioned consensus
sequence. Furthermore, the presence at this site of one of the
two serine residues subject to PKC-dependent phosphorylation
suggests that the level of MRP degradation by leishmanolysin
in Leishmania-infected macrophages may depend on the state
of effector domain phosphorylation.
EXPERIMENTAL PROCEDURES
Reagents—Pepstatin A, poly-L-lysine (;2600 Da), fatty acid-free bo-
vine serum albumin, and horseradish peroxidase-conjugated goat anti-
rabbit IgG were purchased from Sigma. Aprotinin, leupeptin, and phen-
ylmethylsulfonyl fluoride were purchased from Roche Molecular
Biochemicals (Rotkreuz, Switzerland), and 1,10-phenanthroline (ortho-
phenanthroline (OPA)) was from Fluka (Buchs, Switzerland). The hy-
droxamate-derivatized dipeptide Cbz-Tyr-Leu-NHOH (17) was a gift of
Dr. Jacques Bouvier (Novartis, St. Aubin, Switzerland). The
pBB131NMT plasmid was a gift from Dr. Jeffrey Gordon (Washington
University School of Medicine, St. Louis, MO). Construction of the
plasmid pET3dMRPHis has been described elsewhere (18). Escherichia
coli strain JM109(DE3) and the HisBind resin were obtained from
Novagen (Madison, WI). Pfu DNA polymerase was from Stratagene (La
Jolla, CA). The NcoI and BamHI restriction enzymes and T4 DNA
ligase were from New England Biolabs Inc. (Beverly, MA). The Qia-
quick kit for extraction of DNA from agarose gels was obtained from
QIAGEN Inc. (Basel, Switzerland); phenyl-Sepharose was from Amer-
sham Pharmacia Biotech (Uppsala, Sweden); and oligonucleotide prim-
ers were from Microsynth (Balgach, Switzerland).
Leishmanolysin—Proteolytically active, glycosylphosphatidylinosi-
tol-anchored leishmanolysin from Leishmania major LEM513 that mi-
grated as a single 63-kDa band on SDS-polyacrylamide gels was puri-
fied as described previously (16).
Mutagenesis—Manipulation of DNA followed standard procedures
(19). To delete the effector domain in the MRP gene, the megaprimer
method was used (20, 21). Accordingly, three primers were synthesized:
the first primer covers the sequences adjacent to the area to be deleted
(59-AGGAATCACCGGGGGCGA9); the “upstream” primer (59-TTAAT-
ACGACTCACTATAGGG-39) is directed against the T7 promoter region
of the pET plasmid, whereas the “downstream” primer (59GCTAGT-
TATTGCTCAGCGGT-39) is complementary to the transcription termi-
nation region of the pET plasmid. The deletion mutation was intro-
duced by polymerase chain reaction using Pfu DNA polymerase and the
pET3dMRPHis plasmid (18) as the template. Guidelines provided by
the supplier of the Pfu DNA polymerase were followed. In the first
round of polymerase chain reaction, the mutagenic primer and the
upstream primer were used to generate a megaprimer that was purified
by agarose gel electrophoresis, followed by QIAGEN extraction. In the
second round of polymerase chain reaction, the megaprimer and the
downstream primer were employed. The reaction product was purified
as described above; double-digested with NcoI/BamHI; and after puri-
fication, ligated with the NcoI/BamHI-double-digested pET3dMRPHis
plasmid using T4 DNA ligase. The ligation mixture was used to trans-
form E. coli strain JM109(DE3) by electroporation. The bacteria were
plated on LB agar in the presence of 50 mg/ml ampicillin, and transfor-
mants harboring the plasmid (named pET3dMRPD(82–112)His) were
selected based on their ability to express high levels of the unmyristoy-
lated form of MRP-D(82–112) (amino acid residues are numbered start-
ing from the N-terminal Gly residue of MRP). Plasmid DNA from
several colonies was sequenced (Microsynth) to confirm deletion of the
effector domain in the MRP gene.
Recombinant MRPs—For recombinant unmyristoylated MRP and
MRP-D(82–112), we used MRP constructs containing the thrombin-
cleavable His tag at the C terminus (LVPRGSSSGHHHHHH), which
were expressed in E. coli JM109(DE3) as described above. To obtain
myristoylated MRP, the pET3dMRPHis plasmid was electroporated
into E. coli JM109(DE3)pBB131NMT, a strain harboring a plasmid
coding for myristoyl-CoA:protein N-myristoyltransferase; and transfor-
mants growing in the presence of 50 mg/ml ampicillin and kanamycin
each were screened for expression of myristoylated MRP after induction
with isopropyl-b-D-thiogalactopyranoside. Large-scale cultures for the
production of recombinant proteins were grown, induced, and harvested
as described (18, 22). MRPs were purified as described (18) using a
modification of a previously published procedure (22). Briefly, cells were
lysed, and the supernatant was applied to a HisBind column saturated
with Ni21. Proteins were eluted with an imidazole gradient and applied
to a phenyl-Sepharose column. Myristoylated MRP is retained on the
column in the presence of 3 M NaCl and eluted by decreasing the NaCl
concentration to 1.5 M. The unmyristoylated proteins, on the other
hand, are not retained in the presence of 3 M NaCl and elute in the
flow-through of the column. Fractions containing the purified proteins
were combined, dialyzed in the presence of 2.5 mM imidazole (pH 7.4),
concentrated, frozen in aliquots in liquid nitrogen, and stored at 280 °C
until used.
MRP is a highly anionic protein despite the presence of a basic
cluster within the effector domain and thus exhibits anomalous migra-
tion on SDS gels. The calculated molecular mass of native murine MRP
(myristoylated, 199 amino acids) is 20,244 Da, but it is recognized as a
42–45-kDa doublet on Western blots (23, 24). The His-tagged MRP
constructs used in this study also exhibit anomalous migration (18).
Unmyristoylated MRP contains 214 residues with a calculated molec-
ular mass of 21,698 Da and migrates on 15% polyacrylamide gels with
an apparent molecular mass of 46 kDa; myristoylated MRP has a
calculated molecular mass of 21,908 Da and an apparent molecular
mass of 48 kDa. Unmyristoylated effector domain-deficient MRP
(MRPD(82–112)), in which the 24 amino acid residues of the effector
domain and flanking residues 82–85 (KETP) and 110–112 (EGG) are
deleted, has 183 residues, a calculated molecular mass of 18,061 Da,
and an apparent molecular mass of 39 kDa. Phosphorylation of MRPs
was performed with the catalytic subunit of PKC as described previ-
ously (25, 26).
Effector Domain Peptides—A 24-amino acid peptide corresponding to
the effector domain of murine MRP (KKKKKFSFKKPFKLSGLS-
FKRNRK) was synthesized using solid-phase Fmoc (N-(9-fluorenyl)me-
thoxycarbonyl) chemistry in an Applied Biosystems 431A peptide syn-
thesizer (Perkin-Elmer International Inc., Rotkreuz, Switzerland). The
crude polypeptide was purified by reversed-phase HPLC on a Vydac C18
column (250 3 10 mm) using a 0.1% trifluoroacetic acid-containing
H2O/acetonitrile gradient with a flow rate of 3 ml/min. Purity was
.90% as determined by HPLC. The corresponding 25-amino acid bo-
vine MARCKS peptide (KKKKKRFSFKKSFKLSGFSFKKNKK) was
purchased from BIOMOL Research Laboratories, Inc. (Plymouth Meet-
ing, PA). The molecular masses of both peptides were confirmed by
mass spectrometry.
Leishmania—L. major promastigotes (strain MRHO/SU/59/P desig-
nated as LV39) were grown at 26 °C in Dulbecco’s minimal essential
medium on blood agar (27). Stationary phase promastigotes were
washed three times in phosphate-buffered saline and resuspended in
phosphate-buffered saline at 106/ml for experiments measuring the
effect of live parasites on recombinant MRP. For preparation of LV39
lysates, washed parasites were resuspended at 1.2 3 106/ml in phos-
phate-buffered saline containing protease inhibitor mixture (PIC; 5
mg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupep-
tin, and 10 mg/ml aprotinin) and sonicated for 10 s. Lysates were then
used directly for incubation with MRP or centrifuged at 80,000 rpm for
20 min at 4 °C in a Beckman Airfuge. The supernatant (referred to as
LV39 SN) was removed and stored at 220 °C until use. For some
experiments, supernatants were heat-inactivated at 95 °C for 5 min,
followed by 5 min on ice and centrifugation at 11,000 3 g for 5 min.
MRP Degradation—For Western blot analysis, 30 ng of myristoy-
lated MRP were incubated with LV39 promastigotes or LV39 lysates in
20 ml of 10 mM Tris-HCl (pH 7.4) and 100 mM NaCl containing 0.4
mg/ml fatty acid-free bovine serum albumin and fresh PIC. Reaction
mixtures were then centrifuged for 5 min at 11,000 3 g, and superna-
tants were removed and heated for 5 min at 95 °C to obtain heat-stable
fractions. After 5 min on ice, samples were centrifuged again for 5 min,
and supernatants were collected for analysis of MRP degradation. For
analysis by Coomassie Blue staining of SDS-polyacrylamide gels, 2 mg
of myristoylated or unmyristoylated MRP were incubated with LV39
SN or purified leishmanolysin in 20 ml of 10 mM Tris-HCl (pH 7.4) and
100 mM NaCl as indicated. Samples were then heated to 95 °C for 5 min,
and heat-stable fractions were obtained as described.
SDS-PAGE and Western Blot Analysis—Western blot analysis was
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performed as described previously (14). The anti-MRP antibody used
recognizes both myristoylated and unmyristoylated MRPs as well as
MRP phosphorylated in vitro by the catalytic subunit of PKC (25).3
Alternatively, MRP and its degradation products were visualized on
SDS-polyacrylamide gels by staining with Coomassie Brilliant Blue R
(Serva, Heidelberg, Germany) and destained with 10% isopropyl alcohol
and 5% acetic acid in H2O. SDS-polyacrylamide gels or films exposed to
chemiluminescent blots were scanned on a ScanJet 4c/T densitometer
(Hewlett-Packard, Geneva, Switzerland) using the Adobe Photoshop
software package and NIH Image 1.60 software.
pH Optimum—For determination of pH optimum, MRP was incu-
bated with leishmanolysin in Britton-Robinson universal buffer (28)
containing 15 mM each boric acid, sodium citrate, sodium barbital, and
NaH2PO4 adjusted from pH 4 to 12 with NaOH.
Mass Spectrometry—Unmyristoylated MRP, MRP effector domain
peptide, or MARCKS effector domain peptide was incubated with or
without leishmanolysin in 10 mM NH4 acetate buffer (pH 7.0) as indi-
cated. Reactions were terminated by heating to 95 °C for 5 min. One ml
of sample was placed into a well of the mass spectrometer sample plate
and air-dried at room temperature. One ml of a saturated solution of
sinapinic acid (Aldrich, Buchs) in 0.1% trifluoroacetic acid-containing
acetonitrile/H2O (1:2) for MRP samples or a-cyano-4-hydroxycinnamic
acid (Sigma, Buchs) in 0.1% trifluoroacetic acid-containing acetonitrile/
H2O (1:1) for effector domain peptide samples was then added to the
same well and air-dried at room temperature. Matrix-assisted laser
desorption ionization time-of-flight analysis was performed using a
time-of-flight mass spectrometer (Voyager-DE, PerSeptive Biosystem,
Framingham, MA) equipped with a nitrogen laser (l 5 317 nm) to
desorb and ionize the sample; the accelerating voltage was 30 kV. Ion
masses were assigned based on an external mass calibration using two
points that bracketed the mass range of interest for MRP samples or
using bovine insulin (molecular mass [M 1 H]1 5 5734.59 Da) as an
internal standard for effector domain peptide samples. Relative inten-
sities in the matrix-assisted laser desorption ionization spectra are not
strictly proportional to relative abundance of the species due to intrinsic
variability in the desorption process.
RESULTS
MRP Degradation by Live Leishmania Parasites or Parasite
Lysates—To determine whether Leishmania parasites are ca-
pable of exerting a direct degradative effect on MRP, we first
performed Western blot analysis of recombinant myristoylated
MRP incubated with intact live LV39 promastigotes. As shown
in Fig. 1A, MRP levels decreased as a function of parasite
number. Moreover, an ultracentrifugation supernatant frac-
tion of the LV39 lysate (referred to as LV39 SN) appeared to be
nearly as effective as whole parasites. We then compared whole
lysate with LV39 SN or with LV39 SN that had been main-
tained at 95 °C for 5 min. Fig. 1B shows the results of incubat-
ing MRP with these parasite fractions in the presence of PIC
containing pepstatin, phenylmethylsulfonyl fluoride, leupep-
tin, and aprotinin. Both whole lysate and LV39 SN dose-de-
pendently decreased MRP levels, whereas heated LV39 SN was
no longer effective. These results suggested that an enzyme
that is insensitive to the inhibitor mixture might be responsible
for the disappearance of immunoreactive MRP.
Inhibition of MRP Degradation by OPA—One Leishmania
enzyme that is not inhibited by the protease inhibitors listed
above is the surface metalloprotease leishmanolysin. We there-
fore tested the effect of LV39 SN in the presence and absence of
OPA, a zinc chelator that is known to inhibit leishmanolysin
activity for a variety of protein and peptide substrates when
used at millimolar concentrations (17). For the following exper-
iments, we employed an alternative assay that did not rely on
antibody recognition of MRP. This method takes advantage of
the heat stability of MARCKS proteins (5) to remove the ma-3 G. Verge`res, unpublished observations.
FIG. 1. Degradation of MRP by L. major LV39. Myristoylated MRP (30 ng) in buffer containing PIC was incubated for 15 min at room
temperature with increasing numbers of live LV39 promastigotes (A, lanes 5–8) or equivalent amounts of LV39 SN (lanes 1–4) or with whole LV39
lysate (B, lanes 1–4), LV39 SN (lanes 5–8), or heat-inactivated (HI) LV39 SN (lanes 9–12). Reaction mixtures were processed as described under
“Experimental Procedures,” and samples were examined for MRP degradation by Western blot analysis. The asterisks indicate parasite (ps)
equivalent.
FIG. 2. Dose and time dependence of MRP degradation by
LV39 SN. Myristoylated MRP (2 mg) in buffer containing PIC was
incubated for 15 min at room temperature with increasing concentra-
tions of LV39 SN in the absence (A, lanes 1–4) or presence (lanes 5–8)
of 2 mM OPA or for increasing amounts of time with LV39 SN equiva-
lent to 106 parasites in the absence (B, lanes 1–4) or presence (lanes
5–12) of OPA. Heat-stable supernatant fractions of the reaction mix-
tures were assessed for MRP degradation by SDS-PAGE and Coomassie
Blue staining. The asterisk indicates parasite (ps) equivalent.
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jority of LV39 SN proteins before analysis by SDS-PAGE and
Coomassie Blue staining. Indeed, no proteins were revealed in
gels containing LV39 SN alone (data not shown). As demon-
strated in Fig. 2A, LV39 SN decreased MRP levels in a dose-
dependent manner, in agreement with Western blot analysis.
Moreover, this assay allowed the visualization of lower molec-
ular weight degradation products in addition to intact MRP.
Degradation of MRP was completely inhibited by 2 mM OPA.
Fig. 2B shows a representative time course of MRP disappear-
ance and again the inhibition by OPA.
Degradation of Different Molecular Forms of MRP by LV39
SN—The above experiments were performed with myristoy-
lated MRP. We then examined the effect of LV39 SN on differ-
ent molecular forms of MRP including myristoylated MRP,
unmyristoylated MRP, or unmyristoylated MRP lacking the
effector domain (MRPD(82–112)). Each of these proteins was
also tested after phosphorylation by the catalytic subunit of
PKC. Although both myristoylated and unmyristoylated MRPs
were degraded by LV39 SN in an OPA-inhibitable manner,
MRPD(82–112) or the phosphorylated MRPs were largely un-
affected (Fig. 3), suggesting that cleavage occurred within the
effector domain close to a phosphorylation site.
MRP Degradation by Purified Leishmanolysin—As shown in
Fig. 4, the proteolytic activities of purified leishmanolysin and
LV39 SN on MRP were indistinguishable, both in their gener-
ation of degradation products and in their sensitivity to the
metalloprotease inhibitors OPA and Cbz-Tyr-Leu-NHOH, a
more specific inhibitor of leishmanolysin (17). Inhibitors affect-
ing other classes of proteases had no effect. Cleavage of MRP by
leishmanolysin occurred at enzyme/substrate ratios as low as
1:50,000 (data not shown), which compares favorably with con-
ditions used previously with peptide substrates (17). The activ-
ity was dependent on both time and temperature of incubation
and occurred over a broad, mostly alkaline range of pH, which
is characteristic of leishmanolysin (Fig. 5). As expected, no
degradation was observed at pH 12, in agreement with results
demonstrating irreversible inactivation of leishmanolysin at
pH 11.5 and higher (17).
Inhibition of MRP Degradation by Effector Domain Peptides
of MRP or MARCKS—The experiments described above for
effector domain-deficient MRP suggested that this domain was
necessary for leishmanolysin degradation of MRP. A 10-fold
molar excess of peptide covering the effector domain of MRP
completely blocked leishmanolysin-dependent MRP degrada-
tion (Fig. 6). The homologous MARCKS effector domain peptide
was somewhat less efficient. Since these peptides contain a
high number of basic lysine residues, we also tested poly-L-
lysine, which was inactive under the same conditions (Fig. 6).
Mass Spectrometric Analysis of MRP Degradation Prod-
ucts—As shown in Fig. 7, MRP contains two sites,
Ser922Phe93-Lys94-Lys95 (site a) and Ser1032Phe104-Lys105-
Arg106 (site c), that closely correspond to the consensus cleav-
age site of leishmanolysin (17). These sites are both present
within the effector domain and include serines 92 and 103,
which are subject to PKC-dependent phosphorylation. Fig. 8
shows the mass spectrometric analysis of unmyristoylated
MRP and its leishmanolysin-dependent degradation products.
The intact molecule gave a major peak at 22,183.0 Da (Fig. 8A),
considerably larger than its calculated molecular mass of
21,698 Da. The peak at 11,086.2 Da corresponds to the double-
charged species. Two additional peaks (22,058.9 and 21,765.7
Da in Fig. 8A) were consistently observed as shoulders to the
larger peak. Upon incubation with leishmanolysin, a major
product of 9166.0 Da was obtained (Fig. 8B), which exactly
corresponded to the N-terminal peptide expected to result from
cleavage at site a (see Fig. 7) (calculated molecular mass [M 1
H]1 5 9165.8 Da). A minor peak at 13,024.2 Da most probably
FIG. 5. pH dependence of MRP degradation by leishmanolysin.
MRP (5 mM) was incubated with 4 nM leishmanolysin in 15 mM Britton-
Robinson universal buffer at different pH values for 1 h at 37 °C.
Heat-stable supernatant fractions of the reaction mixtures were as-
sessed for MRP degradation by SDS-PAGE and Coomassie Blue
staining.
FIG. 3. Effect of substrate modification on MRP degradation
by LV39 SN. LV39 SN equivalent to 106 parasites with or without 2 mM
OPA was incubated for 1 h at room temperature with 2 mg (5 mM) of
myristoylated (myr) MRP (lanes 1–4), unmyristoylated (unmyr) MRP
(lanes 5–8), or effector domain-deficient MRP (MRPD(82–112)) (lanes
9–12). For lanes 3, 7, and 11, the different MRPs were allowed to
undergo PKC-dependent phosphorylation (1 PKC) prior to addition of
LV39 SN. Heat-stable supernatant fractions of the reaction mixtures
were assessed for MRP degradation by SDS-PAGE and Coomassie Blue
staining.
FIG. 4. Degradation of MRP by leishmanolysin or LV39 SN and
effect of inhibitors of leishmanolysin. MRP (5 mM) was incubated
with LV39 SN equivalent to 106 parasites (lanes 2–4 and 8) or with 40
nM purified leishmanolysin (lanes 5–7 and 9) in the absence or presence
of 2 mM OPA, 2 mM Cbz-Tyr-Leu-NHOH, or PIC for 1 h at room
temperature. Heat-stable supernatant fractions of the reaction mix-
tures were assessed for MRP degradation by SDS-PAGE and Coomassie
Blue staining.
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represents the corresponding C-terminal peptide (expected
value of 13,028.2 Da based on the intact MRP peak at 22,175.2
Da). Generation of these peptides was unaffected by PIC (Fig.
8C), but was completely inhibited by OPA (Fig. 8D). Despite the
heterogeneity observed for intact MRP, the 9166-Da peptide
was always present as a single peak. In addition to this major
peptide, minor peaks (9942.2 and 12,248.0 Da in Fig. 8B) were
consistently observed that could represent the N- and C-termi-
nal peptides resulting from cleavage at site b (calculated mo-
lecular mass [M 1 H]1 of the N-terminal fragment 5 9941.8
Da; expected value for the C-terminal fragment 5 12,252.0 Da
based on the intact MRP peak at 22,175.2 Da). This site is
analogous to a site described earlier for cathepsin B cleavage of
MARCKS (12). Although some other minor peaks were ob-
served, peptides that might result from cleavage at site c (mo-
lecular mass [M 1 H]1 5 10,399 and 11,803 Da) were not
detected. Finally, a similar analysis using LV39 SN in place of
purified leishmanolysin resulted in the generation of identical
products (Fig. 8E), providing strong evidence that leishmano-
lysin is responsible for the MRP-cleaving activity in LV39 SN.
We then performed a similar mass spectrometric analysis
using the effector domain peptide as substrate. As shown in
Fig. 9, incubation with leishmanolysin in the presence of PIC
generated a 2082.4-Da product corresponding to the C-terminal
Phe8–Lys24 peptide (calculated molecular mass [M 1 H]1 5
2082.5 Da) resulting from cleavage at site a. Although earlier
time points were examined in the presence or absence of pro-
tease inhibitors (data not shown), the corresponding N-termi-
nal 893-Da peptide was never observed. In addition to the
2082-Da peptide, a second peak at 1306 Da was observed in
some experiments. This product most probably represents the
C-terminal Leu14–Lys24 peptide (calculated molecular mass [M
1 H]1 5 1305.8 Da) resulting from cleavage at site b. As
mentioned above, this site corresponds to an earlier described
cathepsin B cleavage site in MARCKS (12).
DISCUSSION
We previously demonstrated that macrophages infected with
Leishmania promastigotes express very low levels of MRP (14).
Depletion of intracellular MRP was demonstrated by several
methods, including Western blot analysis, immunofluorescence
microscopy, and biosynthetic labeling with myristic acid. In the
latter case, the appearance of lower molecular weight labeled
products suggested that a proteolytic activity might be respon-
sible for decreasing MRP levels. Such a mechanism appeared
particularly interesting in light of recent studies by Spizz and
Blackshear (13) demonstrating that cellular concentrations of
FIG. 7. Consensus leishmanolysin cleavage sites within the
effector domain of MRP. Shown is the amino acid sequence of the
murine MRP effector domain (ED). Arrows a and c represent leish-
manolysin sites based on a consensus site where P19 is a hydrophobic
amino acid residue and P29 and P39 are basic residues; also shown
(arrow b) is a cleavage site analogous to a previously described cathep-
sin B cleavage site in MARCKS (12). Amino acid residues are numbered
according to their positions within the intact MRP molecule; the corre-
sponding residue positions in the effector domain peptide are indicated
in parentheses.
FIG. 6. Inhibition of leishmanolysin degradation of MRP by
effector domain peptides of MRP or MARCKS. MRP (5 mM) was
incubated with 1 nM leishmanolysin for 1 h at 37 °C in the absence (lane
2) or presence of 5, 20, or 50 mM MRP effector domain peptide (lanes 3–5,
respectively); MARCKS effector domain peptide (lanes 6–8, respective-
ly); or poly-L-lysine (polyLys; lanes 9–11, respectively). Heat-stable
supernatant fractions of the reaction mixtures were assessed for MRP
degradation by SDS-PAGE and Coomassie Blue staining.
FIG. 8. Mass spectrometry of MRP and leishmanolysin-gener-
ated peptides. Unmyristoylated MRP (25 mM) was incubated for 1 h at
37 °C alone (A) or with 10 nM leishmanolysin (B), leishmanolysin plus
PIC (C), leishmanolysin plus 2 mM OPA (D), or LV39 SN equivalent to
106 parasites (E). Heat-stable products were analyzed by mass
spectrometry.
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MARCKS are regulated by proteolysis. A cellular MARCKS-
cleaving enzyme was identified as cathepsin B, and the purified
enzyme was later shown to cleave MARCKS within its basic
effector domain in a cell-free system (12). In the present study,
we investigated whether a proteolytic activity associated with
Leishmania might similarly exhibit MRP-cleaving activity.
MRP and MARCKS contain very homologous effector do-
mains, suggesting that cysteine protease activity could be re-
sponsible for MRP depletion in infected macrophages. Leish-
mania parasites are known to express multiple cysteine
proteases, some of which display cathepsin B-like activity (29,
30). Although MARCKS degradation in fibroblasts could be
inhibited by raising lysosomal pH with NH4Cl (13), we were
unable to inhibit MRP depletion in macrophages treated with
NH4Cl under conditions previously shown in our laboratory to
increase intravesicular pH in infected macrophages (31).2
Moreover, the cysteine protease inhibitor leupeptin was unable
to block MRP degradation by Leishmania parasites or by a
soluble fraction of parasite lysates in a cell-free system. Using
direct staining of MRP and its products on SDS-polyacrylamide
gels, the appearance of at least two molecular species was
observed with apparent molecular masses of ;29–30 and
25–26 kDa. The larger species was generally more strongly
stained than the smaller product. However, it was impossible
to draw information concerning actual molecular size from
such experiments since these smaller fragments apparently
exhibited the same anomalous migration on SDS gels as parent
MRP. Similar conclusions were made by Spizz and Blackshear
(13) for the MARCKS p40 product.
In contrast to the lack of effect of PIC, the zinc chelator OPA
completely blocked MRP degradation by LV39 SN or intact
LV39 promastigotes, supporting our suspicions that MRP-
cleaving activity was due to leishmanolysin, a zinc metallopro-
tease expressed at relatively high density on the surface of
Leishmania promastigotes. Indeed, purified leishmanolysin ex-
hibited similar activity as LV39, and both enzyme activities
were inhibited by a more specific leishmanolysin inhibitor,
Cbz-Tyr-Leu-NHOH. Taken together, our results strongly sug-
gest that the MRP-cleaving activity of LV39 is due to leish-
manolysin. Although leishmanolysin is primarily associated
with the promastigote surface via a glycosylphosphatidylinosi-
tol anchor, a soluble form of the same enzyme has been de-
scribed (32), which may account for its presence in LV39 SN.
The myristoylation state of MRP did not affect leishmanoly-
sin activity, as both myristoylated and unmyristoylated MRPs
were degraded by LV39 SN. However, MRPD(82–112) was not
degraded, suggesting the presence of a cleavage site for leish-
manolysin within the effector domain. In accordance with these
results, an excess of MRP effector peptide (and, to a lesser
extent, of MARCKS effector peptide; see below) protected MRP
from degradation by leishmanolysin. Moreover, MRP subjected
to PKC-dependent phosphorylation was resistant to leishmano-
lysin, strongly suggesting that the unphosphorylated serine
residues of the effector domain are part of the leishmanolysin
recognition sequence. These data are in line with those of Spizz
and Blackshear (12, 13), who found that PKC-phosphorylated
MARCKS was a poor substrate for cathepsin B. Similarly,
decreased susceptibility of MARCKS to cathepsin L after phos-
phorylation by PKC has been reported (33), and regulation of
proteolysis by substrate phosphorylation was also described for
the related GAP-43 protein (34).
The consensus cleavage site of leishmanolysin is character-
ized by a P19 hydrophobic residue and P29 and P39 basic resi-
dues, with P1 often, but not always, a tyrosine residue (17).
There are two consensus cleavage sites for leishmanolysin
within the MRP effector domain, Ser922Phe93-Lys94-Lys95
(site a) and Ser1032Phe104-Lys105-Arg106 (site c), each of which
contains a serine residue subject to phosphorylation (see Fig.
7). The results of mass spectrometric analysis of MRP sug-
gested that the N-terminal peptide resulting from cleavage at
site a was indeed a major reaction product. Minor peaks rep-
resenting the corresponding C-terminal peptide as well as the
C- and N-terminal peptides resulting from cleavage at site b
were also consistently observed. Interestingly, Lys982Leu99
corresponds to a major site of MARCKS effector peptide cleav-
age by purified cathepsin B (12). We can rule out a possible
effect of contaminating cysteine protease in our studies because
the same peak was observed in samples containing leupeptin,
but disappeared in the presence of OPA. Peptides resulting
from cleavage at site c were never detected. Results suggesting
that leishmanolysin cleaves MRP at site a were further con-
firmed by the use of the MRP effector peptide as substrate. In
this case, the C-terminal peptide product resulting from cleav-
age between Ser7 and Phe8 was detected. The seven-amino acid
N-terminal peptide containing five lysine residues was never
observed. The short N-terminal peptide resulting from cathep-
sin B cleavage of the MARCKS effector domain peptide was
also undetectable using an alternative method, HPLC (12),
suggesting that further degradation may occur within these
hydrophilic fragments. As for intact MRP, a second product of
the effector domain peptide, most probably resulting from
cleavage at site b, was also observed, although not in all exper-
iments (data not shown).
We cannot presently explain the difference in the calculated
molecular mass of MRP and our results (21,698 versus 22,183
Da) or the finding of at least three peaks in the recombinant
preparation. Since sequencing results obtained for our con-
FIG. 9. Mass spectrometry of MRP effector domain peptide
and leishmanolysin-generated fragments. The MRP effector do-
main peptide (30 mM) was incubated alone (A) or with 10 nM leishmano-
lysin plus PIC (B) for 1 h at 37 °C. Heat-stable reaction products were
analyzed by mass spectrometry using bovine insulin as an internal
standard.
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structs are consistent with published data,3 this could be due to
heterogeneity that occurs during synthesis or to modification of
the C-terminal portion of the protein (which includes the His
tag) during purification or mass spectrometric analysis.
A recent study of the crystal structure of L. major leishmano-
lysin revealed the presence of a large region of negative charge
surrounding the active-site cleft (35), which might suggest
binding to basic substrates such as the N-terminal portion of
the MARCKS or MRP effector domains. Surprisingly, we were
unable to demonstrate significant degradation of the MARCKS
effector peptide by spectrometric analysis under conditions
used to assess cleavage of the MRP peptide (data not shown).
The MARCKS effector domain contains two identical Ser-Phe-
Lys-Lys sequences and might have been expected to exhibit
high sensitivity to leishmanolysin based on our results with
MRP. One must, however, consider the possibility that the
additional amino acid residue present in the MARCKS effector
domain (an arginine at position 7 immediately prior to the
putative Ser82Phe9 cleavage site) might influence enzyme
binding and/or activity. In agreement with these mass spec-
trometry results, we found that the MARCKS effector domain
peptide was a somewhat less efficient inhibitor of MRP degra-
dation when compared with the MRP peptide, suggesting that
leishmanolysin exhibits some selectivity for MRP as substrate.
However, it will be important to examine the effect of leish-
manolysin on recombinant MARCKS protein to confirm this
conclusion.
The question remains as to how leishmanolysin, which is
presumably restricted to the phagosomal/phagolysosomal com-
partment, might have access to MRP within the macrophage.
Spizz and Blackshear (12) addressed a similar question in
attempting to explain how fibroblast lysosomal cathepsin B
would be expected to exert MARCKS-cleaving activity since
MARCKS, like MRP, is generally thought to be confined to the
cytosol, where it associates with different membranes and or-
ganelles. A putative LAMP1-specific sequence was identified
within the MARCKS sequence, which might allow targeting to
lysosomes, resulting in eventual uptake and processing by ca-
thepsin B, but this remains to be demonstrated. However, it
has been shown that Leishmania promastigotes are contained
within a LAMP1-negative compartment of host macrophages
(36). Moreover, leishmanolysin displayed a pH optimum of 6–9,
with little MRP-cleaving activity at pH 4, suggesting that deg-
radation would be less efficient within the phagolysosome than
within the neutral cytosolic compartment. In this regard, Rittig
et al. (37) recently reported that some intracellular promastig-
otes of L. major may be localized in the cytosol of infected
macrophages. Alternatively, one might hypothesize that a low
level of leishmanolysin is somehow released from the promas-
tigote (perhaps during parasite death) and eventually finds its
way into the cytosol. This would not require a high percentage
of the total enzyme present on the one to five parasites in each
cell. Indeed, we showed that an enzyme/MRP substrate ratio as
low as 1:50,000 can result in significant proteolysis in a cell-
free system. As the total MRP present in a macrophage varies
from ;0.1 to 1 ng/mg of total cell protein depending on the state
of cell activation (14), and as L. major promastigotes express up
to 5 3 105 molecules of leishmanolysin/cell (16), it can be
calculated that as little as 0.001–0.01% of the total enzyme
might be sufficient to cause detectable MRP depletion in in-
fected macrophages.
We reported that Leishmania donovani was considerably
less efficient than LV39 in down-regulating MRP expression in
infected macrophages (14). Similarly, amastigotes of LV39
were less active than their promastigote counterparts.2 In this
regard, it should be noted that promastigotes of some L. dono-
vani strains, including LV636 used in our studies, naturally
express lower levels of leishmanolysin than LV39 (38)2 and
that amastigotes of LV39 express 100-fold less enzyme than
promastigotes (39), which reinforces the idea that the proteo-
lytic degradation of MRP observed with infected macrophages
is in fact due to leishmanolysin. Definitive proof may require
the generation of a leishmanolysin knockout parasite in which
all of the multiple gene copies encoding leishmanolysin are
deleted or the development of specific inhibitors of leishmano-
lysin that are membrane-permeable and nontoxic for
macrophages.
Taken together, our results clearly demonstrate that the
PKC substrate MRP is an excellent leishmanolysin substrate.
Definition of one major cleavage site within the MRP effector
domain may provide important information for further charac-
terization of leishmanolysin enzyme activity as well as for
identification of other potential physiologic substrates in the
macrophage or within the sand fly vector. Moreover, the MRP
cleavage site defined in our studies may provide the basis for
developing more potent and specific inhibitors of leishmanoly-
sin and possibly of the parasite itself. Although MRP degrada-
tion by leishmanolysin remains to be demonstrated in vivo, the
possibility that functional alterations observed in Leishmania-
infected macrophages are related to decreased MRP levels
must be considered.
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